Previous Page  6 / 63 Next Page
Information
Show Menu
Previous Page 6 / 63 Next Page
Page Background

% OS OS

Study

nº pts Loc Adv X+Gem Gem p

Gem+/-5FU bolus

(Berlin,2002)

362 10% 6,7m 5,4m 0,09

Gem+/-5FU/Lv

(Riess, 2005)

466

5,9m 6,2m 0,68

Gem +/-Capec.

(Hermann,2005)

319 21% 8,4m 7,3m 0,31

Gem+/-Capec.

(Cunningham,2009)

533 30% 7,1m 6,2m 0,08

Gem+/-Cisplat.

(Heinemann, 2003)

190 21% 7,5m 6 m 0,12

Gem+/-Oxaliplat.

(Louvet, 2004)

313 31% 9 m 7,1m 0,13

Gem+/-Oxaliplat. (

Poplin,ASCO-06)

576 10% 5.9m 4,9m 0,16

Gem+/-Cisplat.

(Colucci, 2010)

400 16% 7,2m 8,3m NS

Gem+/Marimasmat

(Bramhall,02)

239 28% 5,5m 5,5m 0,95

Gem+/-Tifarbinib

(Van Cutsem,04)

688 24% 6,4m 6,1m 0,75

Gem+/-Exatecan

(O´Reilly,2004)

349 21% 6,7m 6,2m 0,52

Gem+/-CPT-11

(Rocha-Lima, 2004)

360 14% 6,3m 6,6m 0,79

Gem+/-Pemetrexed

(Richards, 04)

565 9% 6,2m 6,3m 0,68

Gem+/-Cetuxi

(Philip, ASCO-07 )

735 21% 6,4m 5,9m 0,14

Gem+/-Beva

(Kindler, ASCO-07)

602 16% 5,8m 6,1m 0,78

Gem-Erlo+/-Beva

(Vervenne,ASCO-08)

607 15% 7,1m 6m 0,2

Gem+/- Axitinib

(Kindler, JCO 2011)

632 18% 8,5m 8,3m 0,5

Gem+/- Erlotinib

(Moore, 2007)

569 24%

6,2m 5,9m 0,02

Advanced pancreatic cancer

Phase III Gem vs Gem+2nd drug